The reported study in Cell Death and Disease demonstrates that OLE, derived from PM20D1, restores microglial barrier formation around amyloid plaques in C. elegans and mouse models, improving mobility and memory tasks. This is strictly preclinical work with no randomized controlled human data; sample sizes are small by design in worm and rodent experiments, and conflicts of interest are unstated beyond institutional patents. While the single-cell analysis highlights microglia-specific responses, the coverage underplays how similar microglial reprogramming attempts, such as those targeting TREM2 or CSF1R pathways, have repeatedly failed to translate beyond rodents. Related work in Nature Neuroscience (2023) on PM20D1 lipid signaling and a 2024 Cell Reports study on neuroinflammation reversal both underscore that amyloid containment alone rarely alters cognitive decline in humans. The true gap is the absence of discussion on off-target neuronal effects and long-term microglial exhaustion, patterns seen across decades of anti-amyloid trials. This positions OLE as an intriguing mechanistic probe rather than imminent therapy, urging focus on human iPSC-microglia validation next.